Company Profile
Immuneering Stock Price, News & Catalysts
- Ticker:
- IMRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.37 USD (-10.37%)
Close
Last updated: November 5, 2026
277M USD
Market cap
Why the stock is moving
The latest monitored company update is āAtebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presentedā¦.ā The corresponding closing-price reaction is not yet available.
Company overview
Deep Cyclic Inhibitors
Immuneering is a late-stage clinical oncology company developing Deep Cyclic Inhibitors for RAS-, RAF- and other MAPK-driven cancers. The approach is designed to produce durable pathway inhibition while limiting resistance, cachexia and treatment-related toxicity.
Atebimetinib
Atebimetinib is an oral, once-daily MEK inhibitor and Immuneering's lead candidate. The drug is designed for combination use across multiple solid tumors rather than as a narrowly targeted monotherapy.
Pancreatic Cancer Development
The global randomized MAPKeeper 301 pivotal Phase 3 trial evaluates atebimetinib with modified gemcitabine and nab-paclitaxel as first-line treatment for metastatic pancreatic cancer. The pipeline also includes additional atebimetinib combinations and preclinical programs.
Lung Cancer Expansion
Immuneering is also evaluating atebimetinib with the PD-1 antibody cemiplimab in non-small cell lung cancer. This program tests whether deep cyclic MEK inhibition can improve immune-checkpoint activity in MAPK-driven tumors while preserving tolerability.
Future catalysts
- First patient dosing in the Phase 2 atebimetinib-plus-cemiplimab lung cancer study in the fourth quarter of 2026.
- Updated Phase 2 atebimetinib-plus-modified gemcitabine/nab-paclitaxel data in first-line pancreatic cancer in the first half of 2027.
- Start of IND-enabling studies for the next Deep Cyclic Inhibitor candidate in mid-2027.
- Preliminary data from the Phase 2 atebimetinib-plus-cemiplimab lung cancer study in late 2027.
- Topline results from the Phase 3 MAPKeeper 301 pancreatic cancer trial in mid-2028, with potential acceleration if enrollment remains ahead of schedule.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Immuneering (IMRX)?
Immuneering (IMRX) most recently closed at 3.37 USD, a -10.37% move versus the previous session.
What is the market cap of Immuneering (IMRX)?
Immuneering currently has a market capitalization of 277M USD on BioPharmSignal.
What does Immuneering do?
Deep Cyclic Inhibitors Immuneering is a late-stage clinical oncology company developing Deep Cyclic Inhibitors for RAS-, RAF- and other MAPK-driven cancers. The approach is designed to produce durable pathway inhibition while limiting resistance, cachexia and treatment-related toxicity. Atebimetinib Atebimetinib is an oral, once-daily MEK inhibitor and...
On which exchange is IMRX stock listed?
Immuneering (IMRX) is associated with NASDAQ, United States, Biopharma.
What is PD-1?
Lung Cancer Expansion Immuneering is also evaluating atebimetinib with the PD-1 antibody cemiplimab in non-small cell lung cancer.
Which conditions is Immuneering targeting with PD-1?
Immuneering is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Immuneering describe recent progress with PD-1?
First patient dosing in the Phase 2 atebimetinib-plus-cemiplimab lung cancer study in the fourth quarter of 2026. Updated Phase 2 atebimetinib-plus-modified gemcitabine/nab-paclitaxel data in first-line pancreatic cancer in the first half of 2027. Start of IND-enabling studies for the next Deep Cyclic Inhibitor candidate in mid-2027. Preliminary data from...
What is atebimetinib?
Atebimetinib Atebimetinib is an oral, once-daily MEK inhibitor and Immuneering's lead candidate.